To avoid genomic DNA amplification, at least one primer is designed crosses the junction of exons according to the conserved region of a specific gene with all variants.

Confirmed in positive organizations; screened the primer with high specificity and high sensitivity.

The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD8, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD8 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas. Immune Checkpoint
Immune Checkpoint Detection: Antibodies    Immune Checkpoint Detection: ELISA Antibodies    Immune Checkpoint Detection: IHC Antibodies    Immune Checkpoint Detection: FCM Antibodies    Immune Checkpoint Detection: WB Antibodies
Immune Checkpoint Proteins
Immune Checkpoint Targets    Co-inhibitory Immune Checkpoint Targets Immunotherapy    Cancer Immunotherapy    Targeted Therapy